SCHEMBL1640573

SCHEMBL1640573

CNC(=O)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 13/20 0.65
BRD2 P25440 3/20 0.65
BRD3 Q15059 3/20 0.65
BRDT Q58F21 3/20 0.65
TRIM24 O15164 1/20 0.52
BRD1 O95696 1/20 0.52
CCL2 P13500 1/20 0.52
TAF1 P21675 1/20 0.52
SMARCA2 P51531 1/20 0.52
SMARCA4 P51532 1/20 0.52
BRPF1 P55201 1/20 0.52
EP300 Q09472 1/20 0.52
BPTF Q12830 1/20 0.52
CACNA1C Q13936 1/20 0.52
ATAD2 Q6PL18 1/20 0.52
PBRM1 Q86U86 1/20 0.52
TAF1L Q8IZX4 1/20 0.52
CREBBP Q92793 1/20 0.52
KAT2A Q92830 1/20 0.52
KAT2B Q92831 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640326 0.88 HSP90AA1 (0.58) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1641827 0.86 BRD4 (0.57) BRD4BRD2BRD3BRDTMAPT
SCHEMBL1642053 0.85 MAPT (0.59) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1642389 0.85 EGLN1 (0.48) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1640352 0.84 LMNA (0.55) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1641959 0.84 KDM4E (0.48) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1641854 0.83 KDM4E (0.53) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1641721 0.83 KDM4E (0.53) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1641629 0.83 BRD4 (0.59) BRD4BRD2BRD3BRDTALDH1A1
SCHEMBL1640540 0.83 KDM4E (0.53) BRD4BRD2BRD3BRDTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
EP-2306828-A1 PROLYL HYDROXYLASE INHIBITORS Glaxosmithkline LLC (US) 2011-04-13 EP disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 BRD4 3195/4885BRD2 2768/4885BRD3 3060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.